{"cited_by_count":1552850,"description":"This cluster of papers covers a wide range of statistical methods and design considerations in the context of clinical trials and drug development. It includes topics such as controlling the false discovery rate, adaptive trial designs, noninferiority trials, biomarkers, phase I trials, multiple testing, Bayesian methods, sample size determination, composite endpoints, and pharmacokinetic/pharmacodynamic modeling.","display_name":"Statistical Methods in Clinical Trials","domain_id":"3","external_ids":{"openalex":"https://openalex.org/T11235","wikipedia":"https://en.wikipedia.org/wiki/Clinical_trial"},"field_id":"26","id":"T11235","keywords":[{"display_name":"clinical trial design","id":"clinical-trial-design","score":0.2813,"url":"https://openalex.org/keywords/clinical-trial-design"},{"display_name":"sample size determination","id":"sample-size-calculation","score":0.2074,"url":"https://openalex.org/keywords/sample-size-calculation"},{"display_name":"trial design","id":"trial-design","score":0.3078,"url":"https://openalex.org/keywords/trial-design"},{"display_name":"multiple comparisons","id":"multiple-testing","score":0.2467,"url":"https://openalex.org/keywords/multiple-testing"},{"display_name":"cancer clinical trials","id":"cancer-clinical-trials","score":0.2773,"url":"https://openalex.org/keywords/cancer-clinical-trials"},{"display_name":"treatment effect estimation","id":"treatment-effect-estimation","score":0.219,"url":"https://openalex.org/keywords/treatment-effect-estimation"},{"display_name":"interim analysis","id":"interim-analysis","score":0.569,"url":"https://openalex.org/keywords/interim-analysis"},{"display_name":"adaptive trial design","id":"adaptive-trial-design","score":0.5814,"url":"https://openalex.org/keywords/adaptive-trial-design"},{"display_name":"type I error control","id":"type-i-error-control","score":0.3569,"url":"https://openalex.org/keywords/type-i-error-control"},{"display_name":"early stopping","id":"early-stopping","score":0.2622,"url":"https://openalex.org/keywords/early-stopping"},{"display_name":"family-wise error rate","id":"family-wise-error-rate","score":0.4854,"url":"https://openalex.org/keywords/family-wise-error-rate"},{"display_name":"time-to-event outcomes","id":"time-to-event-endpoints","score":0.4571,"url":"https://openalex.org/keywords/time-to-event-endpoints"},{"display_name":"blinding","id":"blinding","score":0.2121,"url":"https://openalex.org/keywords/blinding"},{"display_name":"adaptive design","id":"adaptive-design","score":0.2891,"url":"https://openalex.org/keywords/adaptive-design"},{"display_name":"group sequential designs","id":"group-sequential-designs","score":0.9244,"url":"https://openalex.org/keywords/group-sequential-designs"},{"display_name":"equivalence testing","id":"equivalence-testing","score":0.3378,"url":"https://openalex.org/keywords/equivalence-testing"},{"display_name":"type I error rate","id":"type-i-error-rate","score":0.2234,"url":"https://openalex.org/keywords/type-i-error-rate"},{"display_name":"composite endpoints","id":"composite-endpoints","score":0.2428,"url":"https://openalex.org/keywords/composite-endpoints"},{"display_name":"covariate adjustment","id":"covariate-adjustment","score":0.2116,"url":"https://openalex.org/keywords/covariate-adjustment"},{"display_name":"sample size reduction","id":"sample-size-reduction","score":0.2328,"url":"https://openalex.org/keywords/sample-size-reduction"},{"display_name":"treatment allocation","id":"treatment-assignment","score":0.2839,"url":"https://openalex.org/keywords/treatment-assignment"},{"display_name":"dose-finding","id":"dose-finding","score":0.2103,"url":"https://openalex.org/keywords/dose-finding"},{"display_name":"continuous outcomes","id":"continuous-outcomes","score":0.3887,"url":"https://openalex.org/keywords/continuous-outcomes"},{"display_name":"stopping boundaries","id":"stopping-boundaries","score":0.6471,"url":"https://openalex.org/keywords/stopping-boundaries"},{"display_name":"two-stage design","id":"two-stage-design","score":0.5293,"url":"https://openalex.org/keywords/two-stage-design"}],"legacy_keywords":["False Discovery Rate","Adaptive Designs","Noninferiority Trials","Biomarkers","Phase I Trials","Multiple Testing","Bayesian Methods","Sample Size","Composite Endpoints","Pharmacokinetic/Pharmacodynamic Modeling"],"openalex_id":"https://openalex.org/T11235","source_created_date":"2024-01-23T15:27:09","source_updated_date":"2026-10-17T03:02:00","subfield_id":"2613","url":"/topics/T11235","works_api_url":"https://api.openalex.org/works?filter=topics.id:T11235","works_count":86946,"label":"Statistical Methods in Clinical Trials","provider":"openalex","revision":"4c0e1d9cd3ee62c8","taxonomy_revision":"f050b5d4780b1289","title":"Statistical Methods in Clinical Trials","kind":"topic-directory","aeo_cohort":"topic-directory","catalogue_revision":"f050b5d4780b1289","numeric_address":"36240764539643069","address_version":"morton4x16-v1","coordinates":[3,26,2613,11235],"answer_status":"Directory metadata; local answer requires separate source review","truth_status":"Subject descriptor, not a factual answer or a demonstrated knowledge gap","reviewed_answer":null}